Vivo Capital Raises $1.3 Billion For Ninth Fund

By Dan Anderson ● August 19, 2019
  • According to an SEC filing, Vivo Capital has raised more than $1.3 billion for its ninth fund called Vivo Capital Fund IX, L.P.

In an SEC filing, it was revealed that Vivo Capital raised more than $1.3 billion for its ninth fund called Vivo Capital Fund IX, L.P. The SEC filing does not show a target as the total offering amount is listed as “indefinite.”

Launched in 1996, Vivo Capital is a healthcare investment firm focused on investing in and building high-quality companies in the U.S. and Greater China. And with more than $2.2 billion under management, Vivo has a unique multi-pronged strategy of identifying and working with companies with promising development stage and commercial stage therapeutic products in the U.S. and revenue stage companies in Greater China. Vivo Capital has offices in Palo Alto, California, Beijing and Shanghai, China, and Taipei, Taiwan.

Some of the companies in Vivo’s portfolio in the US include Aclaris Therapeutics, AirXpanders, Apellis Pharmaceuticals, Ascendis Pharma, Biohaven Pharma, Eiger, Harmony Biosciences, Impel NeuroPharma, Kala Pharmaceuticals, KalVista Pharmaceuticals, Medeor Therapeutics, Menlo Therapeutics, Minerva Surgical, Nabriva Therapeutics, Outpost Medicine, SentreHEART, Sierra Oncology, Soleno Therapeutics, Surgical Specialties, Synapse BioMedical, and Tricida.


Vivo’s executives include Frank Kung (managing partner), Albert Cha (managing partner), Edgar Engleman (managing partner), Shan Fu (managing partner), Chen Yu (managing partner), Mahendra G. Shah (managing partner), Hwachie Lee (senior advisor), Lawrence Wang (managing director), Gaurav Aggarwal (managing director), Jack Bech Nielsen (managing director), Michael Chang (managing director), Joseph Siletto (managing director), Dan Dan Dong (managing director), Daisy Xu (general director), Qi Zhu (principal), Nina Feng (principal), Andrew D. Goldberg (principal), Kevin Dai (principal), David Liu (principal), Nathan Dau (principal), Daniel Qin (associate), Ethan Zhao (associate), Sue Shao (associate), Vinayak Nikam (associate), Lingfei Zhao (analyst), Yixuan Li (analyst), Tiantian Zhu (analyst), Xiaoyang Li (analyst), Jo Shen (venture partner), and Yuh-geng Tsay (venture partner).